Biogen's Financial Highlights

Biogen Inc. has reported a notable increase in its first-quarter revenue for fiscal 2025, reaching $2.4 billion. This marks a 6% rise compared to the same period in 2024, showcasing the company's robust financial health and strategic growth.

Earnings and Net Income

Despite the revenue growth, GAAP diluted earnings per share experienced a decline year over year, settling at $1.64. The net income attributable to Biogen Inc. for the quarter ending March 31 was reported at $240.5 million.

Leadership's Perspective

"Biogen delivered strong first-quarter results, supporting our strategy for long-term growth. We are encouraged by the transformation in our commercial product portfolio, with approximately 45% of total product revenue in the first quarter derived from important medicines outside of our MS business," stated CEO Christopher Viehbacher, highlighting the company's diversified success.